# Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

> **NCT03057106** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Canadian Cancer Trials Group** · enrollment: 301 (actual)

## Conditions studied

- Lung Cancer Metastatic

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **DRUG:** Platinum-Based Drug

## Key facts

- **NCT ID:** NCT03057106
- **Lead sponsor:** Canadian Cancer Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-28
- **Primary completion:** 2020-02-24
- **Final completion:** 2026-06-30
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057106, "Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03057106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*